About Nautilus Biotechnology, Inc. 
Nautilus Biotechnology, Inc.
Pharmaceuticals & Biotechnology
ARYA Sciences Acquisition Corp III is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. It intends to focus on entities operating in the healthcare industry, particularly the life sciences and medical technology sectors. It has not commenced any operations.
Shareholding Snapshot
Shareholding Compare (%holding) 
Majority shareholders
Strategic Entities
Domestic Funds
Held in 21 Schemes (6.04%)
Foreign Institutions
Held by 24 Foreign Institutions (0.44%)
Strategic Entities with highest holding
Highest Public shareholder
Management
Designation
No Data
Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-15 Million
Pharmaceuticals & Biotechnology
USD 89 Million ()
NA (Loss Making)
NA
0.00%
-0.79
-36.27%
0.49






